The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.

Janet K Peper-Gabriel Marina PavlidouLucia PattariniAizea Morales-Kastresana Thomas J JaquinCatherine GallouEva-Maria HansbauerMarleen RichterHelene LelievreAlix Scholer-DahirelBirgit BossenmaierCeline SancerneMatthieu RiviereMaximilien GrandclaudonMarkus ZettlRachida S Bel AibaChristine RotheVeronique BlancShane A Olwill

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The PD-L1/4-1BB bispecific PRS-344/S095012 efficiently combines checkpoint blockade with a tumor-localized 4-1BB-mediated stimulation burst to antigen-specific T cells, more potent than the combination of mAbs, supporting the advancement of PRS-344/S095012 toward clinical development. See related commentary by Shu et al., p. 3182.

Keyphrases

growth factor
recombinant human
dna damage
high frequency
oxidative stress
cell proliferation
drug induced